NCT04871321View on ClinicalTrials.gov

Biomarker Discovery in Patients With Advanced Biliary Tract Cancer

CompletedOBSERVATIONAL
Enrollment

119

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions
Biliary Tract CancerCholangiocarcinomaGallbladder Cancer
Interventions
DRUG

nab-paclitaxel plus gemcitabine-cisplatin

\- gemcitabine 800mg/m2 + cisplatin 25 mg/m2 + nab-paclitaxel 100mg/m2 on day 1 and day 8, every 21 days

Trial Locations (1)

13496

CHA Bundang Medical Center, Seongnam-si

Sponsors

Collaborators (1)

Dong-A Pharmaceutical
All Listed Sponsors
collaborator

Dong-A Pharmaceutical

INDUSTRY

lead

CHA University

OTHER